R&Q's April 2020 webinar focused on Structuring Performance Evaluation Reports (PERs) under In Vitro Diagnostic Regulation (IVDR). In this blog post, our knowledgeable IVDR experts sat down to provide answers to your questions from the webinar and we hope that they will shed some light on similar questions that you may have on the topic. We all know that the clock is ticking down to the IVDR date of application! May 26, 2022 sounds far away, but it's really not considering the size of the step to IVDR compliance for most IVD companies. The transition from MDD to MDR for medical device manufacturers feels relatively small in comparison to the 85% of IVD companies moving from self-certified to notified body audits, complex regulatory systems, and the expectations of much tighter controls over the web of virtual manufacturing and distribution relationships that IVD companies are accustomed to. R&Q is here to help address any other questions that you may have regarding audits or any other IVDR related topics. Contact us today to find out how we can help! Have more questions on IVDR? Join us on Thursday, June 18 for the discussion during DEVICE L❤️VE Live! #10 Transition to IVDR: How far along should we be? Click here to learn more and register for free. If you were not able to attend this webinar, here's a link where you can sign up to view the on-demand version (and download the slides).
Read Now